Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda Announces Share Repurchase Plan for 2025
- Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed
- Takeda’s Earnings Call Reveals Mixed Performance, Optimistic Outlook
- Vivek Ramaswamy’s Net Worth – The Youngest Billionaire Republican Presidential Candidate
- TAK Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue